Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487468 | 0.89 | IDO1 (0.48) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL1807040 | 0.81 | GRIN2D (0.42) | MAOBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12305 | 0.80 | TP53 (0.44) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL3150164 | 0.78 | IDO1 (0.41) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL231203 | 0.78 | IDO1 (0.41) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL2567905 | 0.78 | TRPA1 (0.42) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL2567350 | 0.78 | MRGPRX4 (0.49) | IDO1AGXTFFAR1ERN1 | |
| SCHEMBL20347891 | 0.78 | TSHR (0.46) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL2901465 | 0.78 | ENPP2 (0.54) | IDO1AGXTMAOB | |
| SCHEMBL30306100 | 0.78 | TRPA1 (0.42) | IDO1AGXTFFAR1ERN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | CHISSO PETROCHEMICAL CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| US-8367792-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8173758-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA | 2011-07-21 | — | — | US | disclosed |
| US-7964692-B2 | Polymer obtained by addition-polymerization initiated by a silicon compound | JNC CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7939617-B2 | Silsesquioxane derivative; electronic material, optical material, optoelectronic material, paint, and primer. | CHISSO CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7863396-B2 | Silicon compounds | CHISSO CORPORATION (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20060100410-A1 | Polymer obtained with silsesquioxane derivative | JNC PETROCHEMICAL CORPORATION (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | ITO KENYA | 2006-04-27 | — | — | US | disclosed |
| US-20060052623-A1 | Having two cyclotetrasiloxne rings connected by O-Si groups obtained through hydrolysis and condensation of trifunctional hydrolyzable silicon compounds; functionalization; fireproofing, thermostability, weathproofing, photostability, dielectric, hardness, strength and chemical resistance | CHISSO CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| US-20050033077-A1 | Production process for silicon compound and the same | JNC CORPORATION (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20040249103-A1 | Silsesquioxane derivatives and process for production thereof | JNC CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040143081-A1 | Novel silicon compounds and process for preparation thereof | JNC CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1428795-A1 | SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052623-A1 | Having two cyclotetrasiloxne rings connected by O-Si groups obtained through hydrolysis and condensation of trifunctional hydrolyzable silicon compounds; functionalization; fireproofing, thermostability, weathproofing, photostability, dielectric, hardness, strength and chemical resistance | STS, PFAS, POLQ | IDO1 900/4885AGXT 2076/4885FFAR1 932/4885 |
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | IDO1 4256/4885AGXT 2940/4885FFAR1 2614/4885 |
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | PIEZO1, PFAS, MCM6 | IDO1 4399/4885AGXT 3032/4885FFAR1 954/4885 |
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | IDO1 2537/4885AGXT 264/4885FFAR1 3730/4885 |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | SFXN1, STS, SRM | IDO1 774/4885AGXT 317/4885FFAR1 2018/4885 |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | IDO1 4256/4885AGXT 2940/4885FFAR1 2614/4885 |
| US-20050033077-A1 | Production process for silicon compound and the same | STS, SMS, SFXN1 | IDO1 1199/4885AGXT 190/4885FFAR1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.